In 2025, biopharma layoffs showed no signs of slowing, instead rising 16% year over year. | In 2025, biopharma layoffs showed ...

A run-up in biotech and drug stocks that sent valuations soaring through the second half of 2025 was looking a bit shaky on ...

One of the biotech industry’s most esteemed venture capitalists anticipates that, after two years of drought, a wave of drug ...

The performance metrics speak volumes. The iShares Biotechnology ETF (NASDAQ: IBB) has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF (NASDAQ: XBI) has ...

O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...

Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro Stoxx 50 Index and smaller names including Valneva SE and Inventiva also ...

BMO pointed to Gilead, Eli Lilly, Regeneron and Merck from the pharma world as names to watch for 2026. “With what felt like sector whiplash in 2025, we remain optimistic into 2026,” the team’s ...

Most biotech firms will be forced to reevaluate foreign relationships and re-route supply chains, or hope for a federal ...

Discover 2026 stock market outlook: earnings-driven gains, potential sector rotation, biotech opportunities, and Fed policy ...

By importing foreign price controls for drugs, he’s compounding making Biden’s mistake.

China's biotech revival is pushing up prices of laboratory monkeys used in drug testing, as renewed R&D activity collides ...